Acrivon Therapeutics, Inc. Common Stock
$1.60
-1.8%Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.2).
Valuation inputs: P/E -1.2, earnings yield N/A, momentum -1.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -69.2%, ROIC -73.0%).
Profitability stack: net margin 0.0%, ROE -69.2%, ROIC -73.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +13.3%, momentum -1.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Acrivon Therapeutics, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Acrivon Therapeutics, Inc. Common Stock Fair Value Envelope
No Revenue Data
ACRV has not reported any revenue values in the available annual periods.
Acrivon Therapeutics, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ACRV has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ACRV has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ACRV has not reported any net profit margin values in the available annual periods.
Acrivon Therapeutics, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Acrivon Therapeutics, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Acrivon Therapeutics, Inc. Common Stock Street Expectations Map
Wall Street analysts project that ACRV stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 21.83, with estimates ranging from a low of 17.00 to a high of 30.00.
The consensus 1-year price target stands at 21.83, with estimates ranging from a low of 17.00 to a high of 30.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Acrivon Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $692K and sold $32K worth of ACRV shares, resulting in $659K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
67.8K
114.34K
0
0.00
+114K
+$114K
6-9 Months
225.0K
407.25K
842
1.52K
+406K
+$406K
9-12 Months
141.9K
170.31K
23.4K
30.96K
+139K
+$139K
Top Buyers
Mirza Mansoor Raza
Officer: Chief Medical Officer
$407K
Blume-Jensen Peter
Director, Officer: President And Ceo
$82K
Shacham Sharon
Director
$24K
Palani Santhosh
Director
$24K
Magovcevic-Liebisch Ivana
Director
$24K
Top Sellers
Blume-Jensen Peter
Director, Officer: President And Ceo
$27K
Miller Mary
Officer: Chief Legal Officer
$3K
Levy Adam D.
Officer: Chief Financial Officer
$1K
Devroe Eric
Officer: Chief Operating Officer
$852
Gamelin Erick
Officer: Chief Development Officer
$560
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $659K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
ACRV has not reported any dividend yield values in the available annual periods.
acrv Dividend History
Learning Layer
Related Guides
Build conviction on ACRV by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.